Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis. Issue 9 (October 2019)

• Record Type: Journal Article
• Authors: Antonelli, Elisabetta; Torti, Gabriele; Bassotti, Gabrio
• Is Part Of: Journal of clinical gastroenterology. Volume 53:Issue 9(2019)
• Publication Date: 2019-10
• Subjects: inflammatory bowel diseases -- Janus kinase inhibitors -- oral treatment -- tofacitinib -- ulcerative colitis; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Digestive organs -- Diseases; Gastroenterology; Periodicals; Periodicals; 616.33005
• DOI: 10.1097/MCG.0000000000001250
• Languages: English
• ISSNs: 0192-0790

Abstract

Abstract : Background: The treatment of ulcerative colitis (UC) is based on conventional therapies (aminosalicylates, corticosteroids, and immunosuppressants) and when these are ineffective, biologic drugs. However, in a substantial portion of patients undergoing treatment with biologic agents there is primary or secondary loss of response. Thus, new therapeutic options are been actively explored; among these, there is interest in the Janus kinase (JAK) inhibitors, small molecules that can be administered orally. Methods: We carried out an extensive literature search concerning the effects of JAK inhibitors for the treatment of patients with UC. Results: Tofacitinib is the drug more extensively studied in this setting, and it was recently approved in Europe for the treatment of moderate to severe UC. The available data suggest that this drug can be effective in obtaining clinical and endoscopic remission in UC patients unresponsive to other treatments, even in those previously treated with biologic drugs. In addition, the drug was able to improve significantly the quality of life of these patients. There are still few data available for the treatment of UC with other JAK inhibitors. Conclusions: The JAK inhibitors, in particular tofacitinib, are a new class of orally administered drugs effective for the treatment of UC. However, more studies are needed to ascertain the safety of tofacitinib in the long term and whether other compounds of this class may be equally effective.